Filing Flows › Gilead Sciences (GILD) › Next earnings date
Gilead Sciences (GILD) earnings: beat the estimate
Gilead Sciences (GILD) reported on Oct 29, 2026 and beat the EPS estimate: $2.55 against $2.19 (+16.2%). Revenue was $8.3B for Q3 2026, +7% year over year. It beat the EPS estimate in 100% of the quarters on record.
The last report
Gilead Sciences reported revenue of $8.3B for the third quarter 2026 (+7% Y/Y), net earnings $2.4B: Total HIV $6.3B, Trodelvy $506M, Total Cell Therapy $355M, Genvoya $339M. How it makes money → · Every quarter →
Gilead Sciences' latest quarter
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
Did Gilead Sciences beat earnings?
Gilead Sciences (GILD) reported on Oct 29, 2026 and beat the EPS estimate: $2.55 against $2.19 (+16.2%).
When does GILD report earnings?
The next date is not set yet.
Does Gilead Sciences usually beat earnings?
It beat the consensus EPS estimate in 100% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.